Stem definition | Drug id | CAS RN |
---|---|---|
1783 | 17560-51-9 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.78 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
BA (Bioavailability) | 65 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 27, 1973 | FDA | UCB INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Fluid retention | 259.53 | 17.30 | 168 | 14860 | 53910 | 56223129 |
Cardiac failure congestive | 255.58 | 17.30 | 201 | 14827 | 87519 | 56189520 |
Hypervolaemia | 241.70 | 17.30 | 125 | 14903 | 26333 | 56250706 |
Pulmonary arterial hypertension | 215.92 | 17.30 | 116 | 14912 | 26387 | 56250652 |
Right ventricular failure | 180.78 | 17.30 | 88 | 14940 | 16291 | 56260748 |
Dyspnoea | 145.67 | 17.30 | 415 | 14613 | 592162 | 55684877 |
Drug ineffective | 122.00 | 17.30 | 47 | 14981 | 918942 | 55358097 |
Pulmonary hypertension | 116.81 | 17.30 | 88 | 14940 | 35856 | 56241183 |
Acute kidney injury | 110.86 | 17.30 | 216 | 14812 | 240547 | 56036492 |
Oedema peripheral | 95.56 | 17.30 | 167 | 14861 | 171087 | 56105952 |
Oedema | 93.08 | 17.30 | 112 | 14916 | 81808 | 56195231 |
Rheumatoid arthritis | 82.37 | 17.30 | 5 | 15023 | 382599 | 55894440 |
Acute respiratory failure | 75.30 | 17.30 | 64 | 14964 | 30930 | 56246109 |
Death | 73.75 | 17.30 | 229 | 14799 | 341197 | 55935842 |
Electrolyte imbalance | 71.91 | 17.30 | 50 | 14978 | 17983 | 56259056 |
Cardiac failure | 70.89 | 17.30 | 98 | 14930 | 81995 | 56195044 |
Calcium deficiency | 70.60 | 17.30 | 21 | 15007 | 996 | 56276043 |
Gastrointestinal haemorrhage | 66.07 | 17.30 | 91 | 14937 | 75860 | 56201179 |
Cardiac failure acute | 61.66 | 17.30 | 35 | 14993 | 8838 | 56268201 |
Dyspnoea exertional | 60.82 | 17.30 | 74 | 14954 | 54615 | 56222424 |
Renal failure | 60.57 | 17.30 | 107 | 14921 | 110393 | 56166646 |
Off label use | 57.74 | 17.30 | 39 | 14989 | 556141 | 55720898 |
Hypoxia | 56.83 | 17.30 | 71 | 14957 | 53826 | 56223213 |
Hospitalisation | 55.18 | 17.30 | 83 | 14945 | 74917 | 56202122 |
Pulmonary oedema | 53.33 | 17.30 | 67 | 14961 | 51076 | 56225963 |
Atrial fibrillation | 51.55 | 17.30 | 99 | 14929 | 108798 | 56168241 |
Torsade de pointes | 50.78 | 17.30 | 35 | 14993 | 12405 | 56264634 |
Hypokalaemia | 49.88 | 17.30 | 90 | 14938 | 94347 | 56182692 |
Chronic kidney disease | 48.54 | 17.30 | 58 | 14970 | 41998 | 56235041 |
Hypotension | 48.51 | 17.30 | 162 | 14866 | 250346 | 56026693 |
Gout | 44.35 | 17.30 | 32 | 14996 | 12189 | 56264850 |
Transfusion | 43.67 | 17.30 | 33 | 14995 | 13487 | 56263552 |
BRASH syndrome | 43.34 | 17.30 | 11 | 15017 | 286 | 56276753 |
Hyperkalaemia | 42.80 | 17.30 | 60 | 14968 | 50805 | 56226234 |
Dermatitis exfoliative | 42.57 | 17.30 | 23 | 15005 | 5276 | 56271763 |
Respiratory failure | 42.04 | 17.30 | 84 | 14944 | 94978 | 56182061 |
Blood potassium decreased | 40.84 | 17.30 | 51 | 14977 | 38621 | 56238418 |
Ascites | 40.43 | 17.30 | 50 | 14978 | 37494 | 56239545 |
Cholecystitis | 39.62 | 17.30 | 32 | 14996 | 14403 | 56262636 |
Joint swelling | 39.57 | 17.30 | 14 | 15014 | 289786 | 55987253 |
Cor pulmonale | 39.09 | 17.30 | 16 | 15012 | 1965 | 56275074 |
Arthralgia | 39.03 | 17.30 | 46 | 14982 | 501623 | 55775416 |
Alopecia | 38.68 | 17.30 | 15 | 15013 | 293443 | 55983596 |
Contraindicated product administered | 38.38 | 17.30 | 3 | 15025 | 186283 | 56090756 |
Urine chloride decreased | 38.14 | 17.30 | 8 | 15020 | 86 | 56276953 |
Systemic lupus erythematosus | 36.82 | 17.30 | 3 | 15025 | 180075 | 56096964 |
Metabolic alkalosis | 36.58 | 17.30 | 17 | 15011 | 2834 | 56274205 |
Therapeutic product effect decreased | 34.16 | 17.30 | 3 | 15025 | 169449 | 56107590 |
Urine sodium decreased | 33.47 | 17.30 | 8 | 15020 | 161 | 56276878 |
Chest pain | 32.57 | 17.30 | 118 | 14910 | 189679 | 56087360 |
Rash | 32.49 | 17.30 | 51 | 14977 | 492996 | 55784043 |
Synovitis | 32.12 | 17.30 | 3 | 15025 | 161302 | 56115737 |
Blood creatinine increased | 30.92 | 17.30 | 67 | 14961 | 80124 | 56196915 |
Cardiac arrest | 30.90 | 17.30 | 70 | 14958 | 86244 | 56190795 |
Oxygen consumption increased | 29.84 | 17.30 | 16 | 15012 | 3615 | 56273424 |
Drug intolerance | 29.57 | 17.30 | 17 | 15011 | 264801 | 56012238 |
Dehydration | 29.18 | 17.30 | 101 | 14927 | 158724 | 56118315 |
Pain in jaw | 28.99 | 17.30 | 44 | 14984 | 39992 | 56237047 |
Arthropathy | 28.50 | 17.30 | 9 | 15019 | 200266 | 56076773 |
Renal impairment | 28.38 | 17.30 | 65 | 14963 | 80648 | 56196391 |
Weight increased | 27.66 | 17.30 | 128 | 14900 | 229575 | 56047464 |
Discomfort | 27.28 | 17.30 | 3 | 15025 | 141758 | 56135281 |
Blood urea increased | 27.00 | 17.30 | 33 | 14995 | 24440 | 56252599 |
Respiratory disorder | 27 | 17.30 | 39 | 14989 | 33918 | 56243121 |
Pericardial effusion | 25.80 | 17.30 | 34 | 14994 | 27141 | 56249898 |
Pericardial haemorrhage | 25.71 | 17.30 | 11 | 15017 | 1509 | 56275530 |
Generalised oedema | 25.52 | 17.30 | 25 | 15003 | 14476 | 56262563 |
Hyperthyroidism | 25.35 | 17.30 | 24 | 15004 | 13328 | 56263711 |
Cardiorenal syndrome | 24.67 | 17.30 | 9 | 15019 | 811 | 56276228 |
Atrial flutter | 24.47 | 17.30 | 20 | 15008 | 9149 | 56267890 |
Musculoskeletal stiffness | 24.07 | 17.30 | 6 | 15022 | 156001 | 56121038 |
Multiple organ dysfunction syndrome | 23.75 | 17.30 | 47 | 14981 | 52723 | 56224316 |
Paracentesis | 23.54 | 17.30 | 9 | 15019 | 924 | 56276115 |
Toxic epidermal necrolysis | 23.16 | 17.30 | 29 | 14999 | 22013 | 56255026 |
Localised oedema | 22.61 | 17.30 | 15 | 15013 | 4994 | 56272045 |
Pulmonary arterial pressure increased | 22.50 | 17.30 | 13 | 15015 | 3392 | 56273647 |
Bone density decreased | 22.46 | 17.30 | 22 | 15006 | 12738 | 56264301 |
Hepatic enzyme increased | 22.16 | 17.30 | 9 | 15019 | 171375 | 56105664 |
Cellulitis | 21.69 | 17.30 | 56 | 14972 | 74893 | 56202146 |
Abdominal distension | 21.44 | 17.30 | 57 | 14971 | 77569 | 56199470 |
Chronic obstructive pulmonary disease | 21.02 | 17.30 | 47 | 14981 | 57368 | 56219671 |
Neutropenia | 20.96 | 17.30 | 8 | 15020 | 158159 | 56118880 |
Vascular parkinsonism | 20.63 | 17.30 | 5 | 15023 | 107 | 56276932 |
Orthopnoea | 20.58 | 17.30 | 15 | 15013 | 5801 | 56271238 |
Oxygen therapy | 20.21 | 17.30 | 10 | 15018 | 1913 | 56275126 |
Pulmonary arterial wedge pressure increased | 19.86 | 17.30 | 6 | 15022 | 300 | 56276739 |
Oxygen saturation decreased | 19.79 | 17.30 | 56 | 14972 | 79011 | 56198028 |
Haemodialysis | 19.35 | 17.30 | 17 | 15011 | 8574 | 56268465 |
Device leakage | 19.35 | 17.30 | 15 | 15013 | 6360 | 56270679 |
Epistaxis | 19.31 | 17.30 | 50 | 14978 | 66973 | 56210066 |
Pleural effusion | 18.96 | 17.30 | 58 | 14970 | 85422 | 56191617 |
Blood aldosterone abnormal | 18.83 | 17.30 | 4 | 15024 | 46 | 56276993 |
Asthenia | 18.82 | 17.30 | 156 | 14872 | 342817 | 55934222 |
Chronic left ventricular failure | 18.71 | 17.30 | 6 | 15022 | 366 | 56276673 |
Blood potassium increased | 18.60 | 17.30 | 23 | 15005 | 17238 | 56259801 |
Brain natriuretic peptide increased | 18.59 | 17.30 | 13 | 15015 | 4713 | 56272326 |
Elephantiasis | 18.39 | 17.30 | 3 | 15025 | 6 | 56277033 |
Renal disorder | 17.94 | 17.30 | 30 | 14998 | 29575 | 56247464 |
Haemoglobin decreased | 17.82 | 17.30 | 77 | 14951 | 134060 | 56142979 |
Restlessness | 17.54 | 17.30 | 28 | 15000 | 26558 | 56250481 |
Syncope | 17.47 | 17.30 | 66 | 14962 | 108133 | 56168906 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure congestive | 254.62 | 17.46 | 220 | 11465 | 79167 | 31606492 |
Acute kidney injury | 168.79 | 17.46 | 338 | 11347 | 279376 | 31406283 |
Fluid retention | 120.67 | 17.46 | 88 | 11597 | 24714 | 31660945 |
Hypokalaemia | 113.10 | 17.46 | 118 | 11567 | 53456 | 31632203 |
Hypervolaemia | 89.30 | 17.46 | 65 | 11620 | 18186 | 31667473 |
Pulmonary hypertension | 86.06 | 17.46 | 66 | 11619 | 19975 | 31665684 |
Hypotension | 83.31 | 17.46 | 212 | 11473 | 204406 | 31481253 |
Cardiac failure | 82.79 | 17.46 | 128 | 11557 | 85825 | 31599834 |
Oedema peripheral | 62.47 | 17.46 | 130 | 11555 | 109709 | 31575950 |
Dyspnoea | 58.92 | 17.46 | 266 | 11419 | 343213 | 31342446 |
Oedema | 58.18 | 17.46 | 75 | 11610 | 42486 | 31643173 |
Blood creatinine increased | 54.86 | 17.46 | 109 | 11576 | 88969 | 31596690 |
Right ventricular failure | 53.47 | 17.46 | 35 | 11650 | 8247 | 31677412 |
Pulmonary arterial hypertension | 52.67 | 17.46 | 37 | 11648 | 9784 | 31675875 |
Blood potassium increased | 45.92 | 17.46 | 41 | 11644 | 15304 | 31670355 |
Venous pressure jugular increased | 44.71 | 17.46 | 15 | 11670 | 760 | 31684899 |
Chronic kidney disease | 44.36 | 17.46 | 62 | 11623 | 37913 | 31647746 |
Polyuria | 38.69 | 17.46 | 28 | 11657 | 7755 | 31677904 |
Drug ineffective | 38.55 | 17.46 | 54 | 11631 | 395519 | 31290140 |
Glomerular filtration rate decreased | 38.10 | 17.46 | 33 | 11652 | 11832 | 31673827 |
Weight increased | 37.89 | 17.46 | 90 | 11595 | 82857 | 31602802 |
Hypovolaemia | 36.86 | 17.46 | 28 | 11657 | 8344 | 31677315 |
Gastrointestinal haemorrhage | 34.96 | 17.46 | 87 | 11598 | 82462 | 31603197 |
Renal failure | 33.73 | 17.46 | 111 | 11574 | 123219 | 31562440 |
Necrotising oesophagitis | 33.58 | 17.46 | 11 | 11674 | 517 | 31685142 |
Blood pressure systolic decreased | 33.09 | 17.46 | 20 | 11665 | 4099 | 31681560 |
Generalised oedema | 32.97 | 17.46 | 30 | 11655 | 11471 | 31674188 |
Dehydration | 31.49 | 17.46 | 106 | 11579 | 119005 | 31566654 |
Hyponatraemia | 30.42 | 17.46 | 77 | 11608 | 73722 | 31611937 |
Blood urea increased | 30.41 | 17.46 | 45 | 11640 | 28967 | 31656692 |
Off label use | 30.34 | 17.46 | 51 | 11634 | 347223 | 31338436 |
Transfusion | 30.26 | 17.46 | 24 | 11661 | 7616 | 31678043 |
Venous pressure jugular decreased | 29.10 | 17.46 | 6 | 11679 | 41 | 31685618 |
Syncope | 28.22 | 17.46 | 82 | 11603 | 85100 | 31600559 |
Orthopnoea | 25.60 | 17.46 | 18 | 11667 | 4763 | 31680896 |
Blood potassium decreased | 24.09 | 17.46 | 30 | 11655 | 16396 | 31669263 |
Cellulitis | 23.99 | 17.46 | 54 | 11631 | 47964 | 31637695 |
Azotaemia | 23.59 | 17.46 | 17 | 11668 | 4675 | 31680984 |
Peripheral swelling | 23.11 | 17.46 | 66 | 11619 | 67799 | 31617860 |
Asthenia | 22.08 | 17.46 | 150 | 11535 | 224605 | 31461054 |
Dizziness | 21.43 | 17.46 | 136 | 11549 | 199011 | 31486648 |
Brain natriuretic peptide increased | 20.79 | 17.46 | 16 | 11669 | 4860 | 31680799 |
Febrile neutropenia | 19.95 | 17.46 | 10 | 11675 | 121839 | 31563820 |
Burkholderia test positive | 19.94 | 17.46 | 9 | 11676 | 1013 | 31684646 |
Blood loss anaemia | 19.93 | 17.46 | 19 | 11666 | 7700 | 31677959 |
Death | 19.69 | 17.46 | 211 | 11474 | 360358 | 31325301 |
Neutropenia | 19.50 | 17.46 | 14 | 11671 | 140350 | 31545309 |
Acute respiratory failure | 19.27 | 17.46 | 36 | 11649 | 28019 | 31657640 |
Atrial fibrillation | 19.24 | 17.46 | 88 | 11597 | 113695 | 31571964 |
Chronic obstructive pulmonary disease | 18.46 | 17.46 | 47 | 11638 | 45119 | 31640540 |
Urine output decreased | 18.39 | 17.46 | 20 | 11665 | 9466 | 31676193 |
Product use in unapproved indication | 18.03 | 17.46 | 7 | 11678 | 99164 | 31586495 |
Blood sodium decreased | 17.86 | 17.46 | 25 | 11660 | 15290 | 31670369 |
Sinus bradycardia | 17.60 | 17.46 | 22 | 11663 | 12065 | 31673594 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure congestive | 447.10 | 14.71 | 370 | 23901 | 135087 | 70769086 |
Fluid retention | 340.42 | 14.71 | 232 | 24039 | 63153 | 70841020 |
Hypervolaemia | 294.08 | 14.71 | 178 | 24093 | 39528 | 70864645 |
Acute kidney injury | 250.20 | 14.71 | 520 | 23751 | 474104 | 70430069 |
Pulmonary arterial hypertension | 232.27 | 14.71 | 143 | 24128 | 32712 | 70871461 |
Right ventricular failure | 207.68 | 14.71 | 116 | 24155 | 22158 | 70882015 |
Pulmonary hypertension | 178.40 | 14.71 | 139 | 24132 | 46397 | 70857776 |
Dyspnoea | 166.34 | 14.71 | 608 | 23663 | 769452 | 70134721 |
Cardiac failure | 143.30 | 14.71 | 209 | 24062 | 143332 | 70760841 |
Oedema | 137.10 | 14.71 | 173 | 24098 | 103408 | 70800765 |
Hypokalaemia | 130.91 | 14.71 | 191 | 24080 | 130997 | 70773176 |
Oedema peripheral | 130.39 | 14.71 | 259 | 24012 | 227832 | 70676341 |
Drug ineffective | 130.10 | 14.71 | 81 | 24190 | 939671 | 69964502 |
Hypotension | 110.37 | 14.71 | 346 | 23925 | 404035 | 70500138 |
Off label use | 95.99 | 14.71 | 69 | 24202 | 742991 | 70161182 |
Gastrointestinal haemorrhage | 86.94 | 14.71 | 163 | 24108 | 137245 | 70766928 |
Rheumatoid arthritis | 83.17 | 14.71 | 4 | 24267 | 291801 | 70612372 |
Acute respiratory failure | 82.93 | 14.71 | 97 | 24174 | 53568 | 70850605 |
Death | 81.07 | 14.71 | 367 | 23904 | 509694 | 70394479 |
Renal failure | 79.71 | 14.71 | 190 | 24081 | 188880 | 70715293 |
Chronic kidney disease | 79.17 | 14.71 | 101 | 24170 | 60956 | 70843217 |
Blood creatinine increased | 78.74 | 14.71 | 160 | 24111 | 142841 | 70761332 |
Transfusion | 69.41 | 14.71 | 55 | 24216 | 18781 | 70885392 |
Calcium deficiency | 66.71 | 14.71 | 20 | 24251 | 756 | 70903417 |
Cardiac failure acute | 66.46 | 14.71 | 52 | 24219 | 17435 | 70886738 |
Dyspnoea exertional | 63.84 | 14.71 | 104 | 24167 | 78326 | 70825847 |
Atrial fibrillation | 59.87 | 14.71 | 168 | 24103 | 184180 | 70719993 |
Blood potassium increased | 59.09 | 14.71 | 59 | 24212 | 27267 | 70876906 |
Blood urea increased | 58.02 | 14.71 | 75 | 24196 | 45834 | 70858339 |
Hypoxia | 56.86 | 14.71 | 109 | 24162 | 93235 | 70810938 |
Dehydration | 55.63 | 14.71 | 187 | 24084 | 225955 | 70678218 |
Pulmonary oedema | 55.01 | 14.71 | 100 | 24171 | 82178 | 70821995 |
Generalised oedema | 54.72 | 14.71 | 51 | 24220 | 21657 | 70882516 |
Weight increased | 53.22 | 14.71 | 193 | 24078 | 242138 | 70662035 |
Infusion related reaction | 52.37 | 14.71 | 4 | 24267 | 197530 | 70706643 |
Blood potassium decreased | 51.58 | 14.71 | 68 | 24203 | 42353 | 70861820 |
Glomerular filtration rate decreased | 50.85 | 14.71 | 48 | 24223 | 20708 | 70883465 |
Hospitalisation | 48.55 | 14.71 | 95 | 24176 | 82473 | 70821700 |
Neutropenia | 48.37 | 14.71 | 14 | 24257 | 257142 | 70647031 |
Orthopnoea | 47.04 | 14.71 | 33 | 24238 | 9375 | 70894798 |
Polyuria | 46.95 | 14.71 | 38 | 24233 | 13368 | 70890805 |
Metabolic alkalosis | 45.47 | 14.71 | 24 | 24247 | 4092 | 70900081 |
Hyperkalaemia | 44.73 | 14.71 | 107 | 24164 | 106484 | 70797689 |
Electrolyte imbalance | 42.23 | 14.71 | 49 | 24222 | 26812 | 70877361 |
Syncope | 41.58 | 14.71 | 138 | 24133 | 165571 | 70738602 |
Arthralgia | 41.28 | 14.71 | 68 | 24203 | 503322 | 70400851 |
Hypovolaemia | 41.13 | 14.71 | 38 | 24233 | 15955 | 70888218 |
Pain in jaw | 39.44 | 14.71 | 60 | 24211 | 42609 | 70861564 |
Venous pressure jugular increased | 38.09 | 14.71 | 15 | 24256 | 1297 | 70902876 |
Gout | 37.91 | 14.71 | 43 | 24228 | 22963 | 70881210 |
Hyponatraemia | 37.24 | 14.71 | 130 | 24141 | 159957 | 70744216 |
Brain natriuretic peptide increased | 37.03 | 14.71 | 27 | 24244 | 8144 | 70896029 |
Urine sodium decreased | 36.37 | 14.71 | 10 | 24261 | 276 | 70903897 |
Cardiorenal syndrome | 36.10 | 14.71 | 15 | 24256 | 1489 | 70902684 |
Azotaemia | 36.01 | 14.71 | 26 | 24245 | 7727 | 70896446 |
Joint swelling | 35.97 | 14.71 | 21 | 24250 | 253190 | 70650983 |
Torsade de pointes | 35.32 | 14.71 | 37 | 24234 | 18079 | 70886094 |
Treatment failure | 35.32 | 14.71 | 4 | 24267 | 144138 | 70760035 |
Urine chloride decreased | 35.06 | 14.71 | 8 | 24263 | 100 | 70904073 |
Respiratory failure | 35.00 | 14.71 | 132 | 24139 | 168603 | 70735570 |
Cellulitis | 34.91 | 14.71 | 93 | 24178 | 98835 | 70805338 |
Cor pulmonale | 34.35 | 14.71 | 16 | 24255 | 2087 | 70902086 |
Alopecia | 33.49 | 14.71 | 13 | 24258 | 198477 | 70705696 |
Chronic left ventricular failure | 33.42 | 14.71 | 12 | 24259 | 803 | 70903370 |
Product use in unapproved indication | 32.74 | 14.71 | 15 | 24256 | 207463 | 70696710 |
BRASH syndrome | 32.35 | 14.71 | 11 | 24260 | 626 | 70903547 |
Oxygen therapy | 31.95 | 14.71 | 16 | 24255 | 2446 | 70901727 |
Asthenia | 31.77 | 14.71 | 266 | 24005 | 457400 | 70446773 |
Necrotising oesophagitis | 31.14 | 14.71 | 11 | 24260 | 702 | 70903471 |
Ascites | 30.72 | 14.71 | 70 | 24201 | 67477 | 70836696 |
International normalised ratio increased | 30.64 | 14.71 | 78 | 24193 | 80648 | 70823525 |
Arthropathy | 30.44 | 14.71 | 7 | 24264 | 150050 | 70754123 |
Febrile neutropenia | 30.38 | 14.71 | 16 | 24255 | 204302 | 70699871 |
Chronic obstructive pulmonary disease | 28.42 | 14.71 | 74 | 24197 | 77567 | 70826606 |
Paracentesis | 28.18 | 14.71 | 12 | 24259 | 1266 | 70902907 |
Rash | 27.92 | 14.71 | 86 | 24185 | 510476 | 70393697 |
Contraindicated product administered | 27.87 | 14.71 | 6 | 24265 | 134606 | 70769567 |
Oxygen consumption increased | 27.16 | 14.71 | 18 | 24253 | 4662 | 70899511 |
Dermatitis exfoliative | 27.00 | 14.71 | 25 | 24246 | 10526 | 70893647 |
Atrial flutter | 26.92 | 14.71 | 34 | 24237 | 20293 | 70883880 |
Chest pain | 26.09 | 14.71 | 161 | 24110 | 251099 | 70653074 |
Musculoskeletal stiffness | 26.06 | 14.71 | 9 | 24262 | 147751 | 70756422 |
Pericardial effusion | 25.68 | 14.71 | 49 | 24222 | 41727 | 70862446 |
Discomfort | 25.64 | 14.71 | 3 | 24268 | 105433 | 70798740 |
Venous pressure jugular decreased | 25.60 | 14.71 | 6 | 24265 | 85 | 70904088 |
Blood sodium decreased | 25.06 | 14.71 | 41 | 24230 | 30957 | 70873216 |
Cholecystitis | 24.88 | 14.71 | 33 | 24238 | 20668 | 70883505 |
Renal impairment | 24.56 | 14.71 | 106 | 24165 | 143831 | 70760342 |
Blood loss anaemia | 23.80 | 14.71 | 27 | 24244 | 14414 | 70889759 |
Pulmonary arterial pressure increased | 23.63 | 14.71 | 16 | 24255 | 4293 | 70899880 |
Peripheral swelling | 22.95 | 14.71 | 149 | 24122 | 236414 | 70667759 |
Left ventricular failure | 22.95 | 14.71 | 21 | 24250 | 8707 | 70895466 |
Hypertension | 22.40 | 14.71 | 42 | 24229 | 295991 | 70608182 |
Systemic lupus erythematosus | 22.23 | 14.71 | 4 | 24267 | 101898 | 70802275 |
White blood cell count decreased | 21.59 | 14.71 | 16 | 24255 | 170125 | 70734048 |
Pericardial haemorrhage | 21.40 | 14.71 | 15 | 24256 | 4253 | 70899920 |
Condition aggravated | 21.40 | 14.71 | 232 | 24039 | 427403 | 70476770 |
Blood pressure systolic decreased | 21.12 | 14.71 | 21 | 24250 | 9650 | 70894523 |
Stomatitis | 20.72 | 14.71 | 9 | 24262 | 128502 | 70775671 |
Respiratory disorder | 20.58 | 14.71 | 43 | 24228 | 39080 | 70865093 |
Malignant neoplasm progression | 20.48 | 14.71 | 8 | 24263 | 121731 | 70782442 |
Renal disorder | 20.26 | 14.71 | 42 | 24229 | 37967 | 70866206 |
Drug hypersensitivity | 20.06 | 14.71 | 37 | 24234 | 262422 | 70641751 |
Haemodialysis | 19.82 | 14.71 | 27 | 24244 | 17339 | 70886834 |
Localised oedema | 19.80 | 14.71 | 18 | 24253 | 7403 | 70896770 |
Pulmonary arterial wedge pressure increased | 19.53 | 14.71 | 7 | 24264 | 466 | 70903707 |
Vascular parkinsonism | 19.53 | 14.71 | 5 | 24266 | 104 | 70904069 |
Lower respiratory tract infection | 19.42 | 14.71 | 7 | 24264 | 111906 | 70792267 |
Dizziness | 19.31 | 14.71 | 243 | 24028 | 463898 | 70440275 |
Oxygen saturation decreased | 19.29 | 14.71 | 85 | 24186 | 116344 | 70787829 |
Blood pressure increased | 18.88 | 14.71 | 22 | 24249 | 188495 | 70715678 |
Urine output decreased | 18.79 | 14.71 | 26 | 24245 | 16944 | 70887229 |
Abdominal distension | 18.56 | 14.71 | 78 | 24193 | 104591 | 70799582 |
Bone density decreased | 18.15 | 14.71 | 21 | 24250 | 11453 | 70892720 |
Gastrointestinal arteriovenous malformation | 18.04 | 14.71 | 8 | 24263 | 931 | 70903242 |
Blood aldosterone abnormal | 17.84 | 14.71 | 4 | 24267 | 46 | 70904127 |
Haemoglobin decreased | 17.38 | 14.71 | 125 | 24146 | 205034 | 70699139 |
Completed suicide | 17.37 | 14.71 | 32 | 24239 | 227103 | 70677070 |
Catheter management | 16.98 | 14.71 | 12 | 24259 | 3447 | 70900726 |
Elephantiasis | 16.79 | 14.71 | 3 | 24268 | 9 | 70904164 |
Cardiomegaly | 16.60 | 14.71 | 30 | 24241 | 24515 | 70879658 |
Device leakage | 16.36 | 14.71 | 18 | 24253 | 9290 | 70894883 |
Pleural effusion | 16.29 | 14.71 | 89 | 24182 | 132775 | 70771398 |
Respiratory distress | 15.97 | 14.71 | 48 | 24223 | 54602 | 70849571 |
C-reactive protein increased | 15.92 | 14.71 | 9 | 24262 | 110508 | 70793665 |
Nasal congestion | 15.84 | 14.71 | 54 | 24217 | 65618 | 70838555 |
Hypokalaemic syndrome | 15.82 | 14.71 | 4 | 24267 | 79 | 70904094 |
Overdose | 15.75 | 14.71 | 21 | 24250 | 169724 | 70734449 |
Cardiac arrest | 15.69 | 14.71 | 101 | 24170 | 159733 | 70744440 |
Paraesthesia | 15.66 | 14.71 | 16 | 24255 | 145521 | 70758652 |
Epistaxis | 15.57 | 14.71 | 73 | 24198 | 102554 | 70801619 |
Dyspnoea at rest | 15.25 | 14.71 | 15 | 24256 | 6804 | 70897369 |
Pericarditis | 15.21 | 14.71 | 5 | 24266 | 84700 | 70819473 |
Multiple organ dysfunction syndrome | 14.89 | 14.71 | 75 | 24196 | 108440 | 70795733 |
None
Source | Code | Description |
---|---|---|
ATC | C03BA08 | CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides, plain |
ATC | C03EA12 | CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents |
FDA PE | N0000175359 | Increased Diuresis |
FDA EPC | N0000175420 | Thiazide-like Diuretic |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004232 | Diuretics |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D045283 | Natriuretic Agents |
MeSH PA | D049993 | Sodium Chloride Symporter Inhibitors |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:50184 | ion-transport inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Renal Disease with Edema | indication | ||
Peripheral Edema due to Chronic Heart Failure | indication | ||
Pulmonary Edema due to Chronic Heart Failure | indication | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Hypercholesterolemia | contraindication | 13644009 | |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Orthostatic hypotension | contraindication | 28651003 | |
Hypokalemia | contraindication | 43339004 | |
Pregnancy-induced hypertension | contraindication | 48194001 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Oliguria | contraindication | 83128009 | |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Hypomagnesemia | contraindication | 190855004 | |
Persistent vomiting | contraindication | 196746003 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Severe diarrhea | contraindication | 409587002 | |
Azotemia | contraindication | 445009001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.66 | acidic |
pKa2 | 1.3 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 12 member 3 | Transporter | INHIBITOR | CHEMBL | CHEMBL | |||||
Solute carrier family 12 member 1 | Transporter | Kd | 8.45 | WOMBAT-PK | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.68 | CHEMBL |
ID | Source |
---|---|
D00431 | KEGG_DRUG |
4018161 | VANDF |
C0025854 | UMLSCUI |
CHEBI:64354 | CHEBI |
CHEMBL878 | ChEMBL_ID |
DB00524 | DRUGBANK_ID |
D008788 | MESH_DESCRIPTOR_UI |
4170 | PUBCHEM_CID |
4838 | IUPHAR_LIGAND_ID |
2627 | INN_ID |
TZ7V40X7VX | UNII |
203794 | RXNORM |
1440 | MMSL |
47402 | MMSL |
5101 | MMSL |
d00299 | MMSL |
002310 | NDDF |
22198003 | SNOMEDCT_US |
387123003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0055 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0055 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5050 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5050 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5600 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-5600 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6172 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6173 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6174 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2215 | TABLET | 2.50 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2215 | TABLET | 2.50 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2216 | TABLET | 5 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2216 | TABLET | 5 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2217 | TABLET | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2217 | TABLET | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6915 | TABLET | 5 mg | ORAL | NDA authorized generic | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6915 | TABLET | 5 mg | ORAL | NDA authorized generic | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6916 | TABLET | 2.50 mg | ORAL | NDA authorized generic | 24 sections |
metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6916 | TABLET | 2.50 mg | ORAL | NDA authorized generic | 24 sections |
METOLAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7138 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
METOLAZONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7139 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-890 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-931 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-999 | TABLET | 2.50 mg | ORAL | NDA AUTHORIZED GENERIC | 24 sections |
METOLAZONE | Human Prescription Drug Label | 1 | 46708-532 | TABLET | 2.50 mg | ORAL | ANDA | 22 sections |
METOLAZONE | Human Prescription Drug Label | 1 | 46708-533 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
METOLAZONE | Human Prescription Drug Label | 1 | 46708-534 | TABLET | 10 mg | ORAL | ANDA | 22 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-023 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-024 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Metolazone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-431 | TABLET | 2.50 mg | ORAL | ANDA | 12 sections |